Latham & Watkins Advises on Carlsmed, Inc.’s US$100.5 Million Initial Public Offering

Carlsmed, Inc., a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, has announced the pricing of its initial public offering of 6,700,000 shares of common stock at an initial price to the public of US$15.00 per share. The gross proceeds to Carlsmed from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Carlsmed, are expected to be US$100.5 million. In addition, the underwriters have a 30-day option to purchase up to an additional 1,005,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP is advising the underwriters in the offering with a capital markets team led by Orange County/Bay Area partners Shayne Kennedy and Ross McAloon, with associates Jacob Walsh, Caitlin Nguyen, Lexi Zintel, and Blake LaClaire.